Teduglutide: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •2 community protocols documented
- •Evidence level: Anecdotal Reports
- •Based on 25 community reports
- •1 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Treatment Duration | Clinical trials evaluated teduglutide over 24 weeks (STEPS trial) with extension studies up to 2+ years. Treatment is intended as long-term therapy. | Patient communities report ongoing long-term use, often for years. Discussions include managing the commitment of daily injections and the practical challenges of reconstitution. Some patients discuss treatment discontinuation concerns. | moderate Long-term safety data is reassuring, with colonoscopy surveillance recommended due to theoretical GI polyp risk. Patients generally report sustained benefit with continued treatment. |
| Parenteral Nutrition Reduction | Clinical trials measured PN volume reduction as a primary endpoint, with 63% of patients achieving 20% or greater reduction in PN volume. | Patient communities focus on the real-world impact of PN reduction on quality of life, including fewer infusion days per week, reduced catheter-related infections, and improved ability to travel and participate in normal activities. | moderate The quality of life impact of even modest PN reduction can be profound for patients who have been dependent on IV nutrition. Community discussions capture this dimension better than clinical trial endpoints. |
Compare these community approaches with published research findings.
Community Protocols
FDA-Approved SBS Protocol
Popular- Route
- Subcutaneous injection
- Dose
- 0.05 mg/kg once daily
- Frequency
- Once daily
- Duration
- Ongoing (long-term treatment)
FDA-approved dose for adults with SBS-IF; dose reduction to 0.025 mg/kg for moderate-severe renal impairment
Pediatric SBS Protocol
Common- Route
- Subcutaneous injection
- Dose
- 0.05 mg/kg once daily
- Frequency
- Once daily
- Duration
- Ongoing
FDA-approved for pediatric patients 1 year and older with SBS-IF requiring parenteral support
Stacking Patterns
Teduglutide + Optimized Oral Nutrition
PopularTeduglutide to promote intestinal adaptation combined with dietitian- guided optimization of oral nutrition to maximize nutrient absorption
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 25+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/ShortBowelSyndrome|Gattex patient experience and PN weaning discussions(accessed 2026-02-16)
- Oley Foundation|Home parenteral and enteral nutrition patient support community(accessed 2026-02-16)
- ASPEN Connect|Clinical nutrition support resources and patient information(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated patient reports and community discussions for teduglutide (Gattex/Revestive). The information below is gathered from SBS patient communities and GI forums. This is not clinical evidence and should not be used as medical guidance.
Teduglutide is an FDA-approved prescription medication for short bowel syndrome-associated intestinal failure. Due to the rare nature of SBS, the patient community is small but closely connected through organizations like the Oley Foundation.
Important Note#
Teduglutide is a prescription medication for a rare, serious condition. Treatment decisions should be made with specialized gastroenterologists experienced in SBS management. This page documents patient-reported experiences, not self-experimentation protocols.
Commonly Reported Patient Outcomes#
SBS patients using teduglutide report:
- PN reduction: The most valued outcome, with many patients achieving meaningful reductions in the number and volume of parenteral nutrition infusions
- Intestinal adaptation: Patients describe gradual improvement in absorption capacity over months of treatment
- Quality of life: Freedom from PN dependence (partial or complete) is described as life-changing
- Injection routine: Daily subcutaneous injection with reconstitution becomes manageable with practice
- GI symptoms: Some patients report increased stool output during initial treatment, which typically stabilizes
Important Caveats#
- SBS is a complex condition requiring specialized medical management
- Response to teduglutide varies based on remaining bowel anatomy and adaptation potential
- Regular colonoscopy surveillance is recommended during treatment
- Cost and insurance coverage are significant barriers for many patients
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Teduglutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.